Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001887954 | SCV002126582 | uncertain significance | Epilepsy, familial adult myoclonic, 5 | 2022-06-05 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 552 of the CNTN2 protein (p.Asp552Gly). This variant is present in population databases (rs375531151, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with CNTN2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1355060). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CNTN2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004039011 | SCV003537952 | uncertain significance | not specified | 2022-08-11 | criteria provided, single submitter | clinical testing | The c.1655A>G (p.D552G) alteration is located in exon 13 (coding exon 12) of the CNTN2 gene. This alteration results from a A to G substitution at nucleotide position 1655, causing the aspartic acid (D) at amino acid position 552 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |